Recent Updates
Recently added Catalysts

Glioma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.4Buniverse median $1.20B
Allocated capital$792M$2.4B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank164/299crowding rank 175

Glioma is uncontested. Nuvation Bio (NUVB) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Safusidenib in phase 3.

There is no public comparable to price it against. NUVB spreads its $2.4B market cap across 3 indications, so $792M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$792M of allocated capital sits in Glioma, ranking it 164th of 299 indications by the money committed to it.

Companies developing drugs for Glioma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NUVBNuvation BioSafusidenibPhase 31$2.4BNo3 26 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Glioma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Glioma has one competitor and a median of $2.4B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Advanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedCancer Pain1 company · $798M · median $4.0BUncontestedMetastatic Head and Neck Squamous Cell Carcinoma1 company · $772M · median $1.5BUncontestedPancreatic Ductal Adenocarcinoma1 company · $768M · median $3.8BUncontestedAdvanced Gastroesophageal Adenocarcinoma1 company · $767M · median $3.8BUncontestedDiffuse Large B-Cell Lymphoma3 companies · $834M · median $351MOrphan cornerCervical Cancer1 company · $848M · median $2.5BUncontestedNon-Muscle Invasive Bladder Cancer (NMIBC)1 company · $723M · median $8.7BUncontested

Glioma pipeline questions

Which biotech companies are developing drugs for Glioma?

Nuvation Bio (NUVB, Safusidenib, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Glioma.

How advanced is the Glioma pipeline?

Of the 1 clinical-stage programme in Glioma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Glioma?

No. NUVB is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Glioma, which is why the indication is classified as uncontested.

When is the next Glioma catalyst?

The next dated catalyst in Glioma is NUVB on 26 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map